Anti-IL6R role in treatment of COVID-19-related ARDS
- PMID: 32290847
- PMCID: PMC7154570
- DOI: 10.1186/s12967-020-02333-9
Anti-IL6R role in treatment of COVID-19-related ARDS
Keywords: ARDS; COVID-19; IL-6; SARS-CoV-2; Tocilizumab.
Conflict of interest statement
PAA has/had a consultant/advisory role for Bristol Myers-Squibb, Roche-Genentech, Merck Sharp & Dohme, Array, Novartis, Merck Serono, Pierre Fabre, Incyte, NewLink Genetics, Genmab, Medimmune, AstraZeneca, Syndax, SunPharma, Sanofi, Idera, Ultimovacs, Sandoz, Immunocore, 4SC, Alkermes, Italfarmaco, Nektar, Boehringer-Ingelheim. He also received research funds from Bristol Myers-Squibb, Roche-Genentech, Array, and travel support from MSD.
IP serves as consultant for Amgen
FMB
Comment on
-
Why tocilizumab could be an effective treatment for severe COVID-19?J Transl Med. 2020 Apr 14;18(1):164. doi: 10.1186/s12967-020-02339-3. J Transl Med. 2020. PMID: 32290839 Free PMC article.
References
-
- The General Office of National Health Commission Office of State TCM Administration. Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 6, Revised). http://www.kankyokansen.org/uploads/uploads/files/jsipc/protocol_V6.pdf. Accessed 18 Feb 2020.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources